zavegepant 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
calcitonin gene-related peptide receptor antagonists	5713	1337918-83-8

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

zavegepant
zavegepant hydrochloride
zavzpret
BHV-3500
BMS-742413
BMS742413
BMS-742413-01

Zavegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.

Molecular weight: 638.82
Formula: C36H46N8O3
CLOGP:
LIPINSKI: 2
HAC: 11
HDO: 3
TPSA: 116.91
ALOGS:
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
March 9, 2023	FDA	PFIZER INC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
FDA EPC	N0000193917	Calcitonin Gene-related Peptide Receptor Antagonist
FDA MoA	N0000193918	Calcitonin Gene-related Peptide Receptor Antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Migraine with aura	indication	4473006	DOID:10024
Migraine without aura	indication	56097005	DOID:12783

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 10MG BASE/SPRAY	ZAVZPRET	PFIZER	N216386	March 9, 2023	RX	SPRAY, METERED	NASAL	7314883	Dec. 5, 2023	ADMINISTRATION OF ZAVEGEPANT FOR ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
EQ 10MG BASE/SPRAY	ZAVZPRET	PFIZER	N216386	March 9, 2023	RX	SPRAY, METERED	NASAL	8481546	Oct. 7, 2031	ADMINISTRATION OF ZAVEGEPANT FOR ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 10MG BASE/SPRAY	ZAVZPRET	PFIZER	N216386	March 9, 2023	RX	SPRAY, METERED	NASAL	March 9, 2028	NEW CHEMICAL ENTITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Calcitonin gene-related peptide type 1 receptor	GPCR	Q16602	CALRL_HUMAN	ANTAGONIST	Ki	10.64		DRUG LABEL	DRUG LABEL

External reference:

ID	Source
CHEMBL2397415	ChEMBL_ID
C584752	MESH_SUPPLEMENTAL_RECORD_UI
11513	IUPHAR_LIGAND_ID
DB15688	DRUGBANK_ID
019338	NDDF
019339	NDDF
4042290	VANDF
C5383284	UMLSCUI
CHEMBL4650220	ChEMBL_ID
11512	INN_ID
1414976-20-7	SECONDARY_CAS_RN
53472683	PUBCHEM_CID
2637955	RXNORM
D11898	KEGG_DRUG
ODU3ZAZ94J	UNII
365618	MMSL
41302	MMSL
d10020	MMSL

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ZAVZPRET	HUMAN PRESCRIPTION DRUG LABEL	1	0069-3500	SPRAY	10 mg	NASAL	NDA	27 sections
ZAVZPRET	HUMAN PRESCRIPTION DRUG LABEL	1	63539-135	SPRAY	10 mg	NASAL	NDA	27 sections